| scholarly article | Q13442814 |
| P50 | author | Patrick F. Sullivan | Q56249782 |
| David W. Threadgill | Q42306006 | ||
| James J. Crowley | Q42841837 | ||
| P2093 | author name string | Wei Wang | |
| Molly A Bogue | |||
| Fernando Pardo-Manuel de Villena | |||
| Howard L McLeod | |||
| Corey R Quackenbush | |||
| Yunjung Kim | |||
| Hyuna Yang | |||
| Daniel E Adkins | |||
| Edwin van den Oord | |||
| Jin Peng Szatkiewicz | |||
| Amanda L Pratt | |||
| P2860 | cites work | Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon 1 subunit | Q24309045 |
| The Mouse Genome Database (MGD): premier model organism resource for mammalian genomics and genetics | Q24616724 | ||
| The UCSC Genome Browser database: update 2011 | Q24625811 | ||
| The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment | Q28256285 | ||
| Sensitization versus tolerance to haloperidol-induced catalepsy: multiple determinants | Q28331508 | ||
| betaCaMKII controls the direction of plasticity at parallel fiber-Purkinje cell synapses | Q28505097 | ||
| Mice with reduced NMDA receptor expression display behaviors related to schizophrenia | Q28510751 | ||
| MTCH2/MIMP is a major facilitator of tBID recruitment to mitochondria | Q28594262 | ||
| PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data | Q29614933 | ||
| Obstetric complications, the putative familial-sporadic distinction, and tardive dyskinesia in schizophrenia | Q48892603 | ||
| CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. | Q52976757 | ||
| The Collaborative Cross, a community resource for the genetic analysis of complex traits | Q56896214 | ||
| Familial occurrence of tardive dyskinesia | Q57655477 | ||
| No Association between Dopamine D4 Receptor Gene –521 C/T Polymorphism and Tardive Dyskinesia in Schizophrenia | Q61877416 | ||
| Long-acting, antipsychotic agents and extrapyramidal side effects | Q67208140 | ||
| Biliary excretion of reduced haloperidol glucuronide | Q68695550 | ||
| Familial tardive dyskinesia | Q72507748 | ||
| Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment | Q72549857 | ||
| Haloperidol-induced neurotoxicity--possible implications for tardive dyskinesia | Q73533445 | ||
| The effect of ovariectomy and long-term estrogen replacement on bladder structure and function in the rat | Q74628925 | ||
| The Mouse Phenome Project | Q81200135 | ||
| Antipsychotic-induced extrapyramidal symptoms and their management | Q81383731 | ||
| Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice. | Q30501284 | ||
| Tardive dyskinesia | Q33280219 | ||
| Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania | Q33583988 | ||
| Regional characterization of energy metabolism in the brain of normal and MPTP-intoxicated mice using new markers of glucose and phosphate transport | Q34437354 | ||
| Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. | Q34560783 | ||
| Toxicogenetics: population-based testing of drug and chemical safety in mouse models | Q34561910 | ||
| Mendelian Inheritance in Man and its online version, OMIM | Q34577589 | ||
| The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? | Q34659357 | ||
| World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia | Q34744755 | ||
| Genomewide association study of movement-related adverse antipsychotic effects | Q35010386 | ||
| Genetic analysis of complex traits in the emerging Collaborative Cross | Q35145475 | ||
| A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex | Q35229075 | ||
| Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis | Q36412015 | ||
| Efficient control of population structure in model organism association mapping | Q36515832 | ||
| Genetic networks controlling the development of midbrain dopaminergic neurons | Q36529472 | ||
| A customized and versatile high-density genotyping array for the mouse. | Q37327534 | ||
| Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans | Q37363157 | ||
| The genetics of quantitative traits: challenges and prospects | Q37544241 | ||
| Behavioral pharmacology of orofacial movement disorders | Q37894923 | ||
| Significance analysis of functional categories in gene expression studies: a structured permutation approach | Q38521075 | ||
| Pharmacokinetics of haloperidol | Q38738913 | ||
| Exploratory behavior models of anxiety in mice | Q39350564 | ||
| Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature | Q39967928 | ||
| Translocation of AIF in the human and rat striatum following protracted haloperidol, but not clozapine treatment | Q40306606 | ||
| TreeQA: quantitative genome wide association mapping using local perfect phylogeny trees. | Q42099256 | ||
| Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat. | Q42515481 | ||
| Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches | Q43256604 | ||
| Topographical assessment and pharmacological characterization of orofacial movements in mice: dopamine D(1)-like vs. D(2)-like receptor regulation | Q43596394 | ||
| Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia | Q44112135 | ||
| The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats | Q44206083 | ||
| Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene ⋆ | Q44414314 | ||
| Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia | Q44984756 | ||
| Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia | Q45177150 | ||
| Antipsychotic drug binding in the substantia nigra: an examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia | Q45298345 | ||
| The UCSC Known Genes | Q46070887 | ||
| Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype | Q46460488 | ||
| P433 | issue | 5-6 | |
| P921 | main subject | genome-wide association study | Q1098876 |
| extrapyramidal symptoms | Q1385411 | ||
| P1104 | number of pages | 14 | |
| P304 | page(s) | 322-335 | |
| P577 | publication date | 2011-12-30 | |
| P1433 | published in | Mammalian Genome | Q1348949 |
| P1476 | title | Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice | |
| P478 | volume | 23 |
| Q41091940 | A Pharmacogenetic Discovery: Cystamine Protects Against Haloperidol-Induced Toxicity and Ischemic Brain Injury |
| Q38630075 | Applicability of gene expression and systems biology to develop pharmacogenetic predictors; antipsychotic-induced extrapyramidal symptoms as an example |
| Q42841690 | Brain levels of the neurotoxic pyridinium metabolite HPP+ and extrapyramidal symptoms in haloperidol-treated mice |
| Q40181690 | Comparative genomic evidence for the involvement of schizophrenia risk genes in antipsychotic effects. |
| Q26823735 | Effects of antipsychotics on dentate gyrus stem cell proliferation and survival in animal models: a critical update |
| Q30445406 | Genetics of adverse reactions to haloperidol in a mouse diallel: a drug-placebo experiment and Bayesian causal analysis. |
| Q38990216 | Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms. |
| Q35987580 | Neurochemical Metabolomics Reveals Disruption to Sphingolipid Metabolism Following Chronic Haloperidol Administration |
| Q48006592 | Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes |
| Q38792346 | Possible biomarkers modulating haloperidol efficacy and/or tolerability |
| Q49460831 | Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges |
| Q38032249 | Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis |
| Q37524743 | Testing two models describing how methylome-wide studies in blood are informative for psychiatric conditions |
| Q36383131 | The Founder Strains of the Collaborative Cross Express a Complex Combination of Advantageous and Deleterious Traits for Male Reproduction |
| Q28543192 | The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans |
| Q39084564 | Therapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation |
Search more.